Surface renderings of baseline tau-PET positivity across diagnostic groups are shown in Fig. 1F for ADNI and for BioFINDER, showing no evidence for tau-PET positivity in amyloid-negative controls, minimally elevated temporal-lobe tau levels in preclinical AD, vs. gradually increasing tau-PET positivity across symptomatic AD patients with MCI and AD dementia. This evidence concerns the gene MAPT and Alzheimer disease.